Meiji Seika Pharma (4919.T)

Executive Summary

Meiji Seika Pharma, a Japanese pharmaceutical company with a legacy dating back to 1946, specializes in anti-infectives and oncology. The company is publicly traded (Ticker: 4919.T) and has a market capitalization of approximately $82 billion. Meiji Seika is renowned for its expertise in small molecule drug discovery, particularly in antibiotics and antifungal agents, with a strong focus on combating antimicrobial resistance (AMR). Its commercial-stage operations and robust pipeline in infectious diseases and oncology position it as a key player in global health, especially in addressing the growing threat of drug-resistant infections.